Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis

Journal of Infectious Diseases

Volumn 207, Issue 5, 2013, Pages 834-841

  Lewis, Russell E ^a,b   Ben Ami, Ronen ^a   Best, Leyla ^a   Albert, Nathaniel ^a   Walsh, Thomas J ^c   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

animal models; immunocompromised; Mucormycosis; posaconazole; subcutaneous; tacrolimus

Indexed keywords

POSACONAZOLE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CUTANEOUS MUCORMYCOSIS; DERMATOMYCOSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; EXPERIMENTAL INFECTION; FEMALE; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; FUNGUS ISOLATION; GROWTH INHIBITION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; MUCORMYCOSIS; NONHUMAN; PRIORITY JOURNAL; RHIZOPUS ORYZAE; SURVIVAL RATE;

ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; DROSOPHILA; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUCORMYCOSIS; RHIZOPUS; TACROLIMUS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84873697234     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis767     Document Type: Article

References (43)

1. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091-1100
2. Bitar D. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15:1395-1401
3. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005; 41:634-53
4. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: Biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47:1041-50
5. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazoleassociated zygomycosis: A significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009; 15:93-7
6. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: From bench to bedside. Clin Infect Dis 2009; 48:1743-51
7. Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother 2011; 55:5018-21
8. Kahan BD. Timeline: Individuality: The barrier to optimal immunosuppression. Nat Rev Immunol 2003; 3:831-8
9. Cowen LE. Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS Pathog 2009; 5:e1000471
10. Steinbach WJ, Cramer RA, Perfect BZ, et al. Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryotic Cell 2006; 5:1091-103
11. Reedy JL, Filler SG, Heitman J. Elucidating the Candida albicans calcineurin signaling cascade controlling stress response and virulence. Fungal Genet Biol 2010; 47:107-16
12. Ma L-J, Ibrahim AS, Skory C, et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet 2009; 5:e1000549
13. Lewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP, Walsh TJ. How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin Infect Dis 2012; 54 (SUPPL1):S67-72
14. Dannaoui E, Afeltra J, Meis JFGM, Verweij PE, Eurofung Network. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother 2002; 46:2708-11
15. Narreddy S, Manavathu E, Chandrasekar PH, Alangaden GJ, Revankar SG. In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes. J Antimicrob Chemother 2010; 65:701-3
16. Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 2003; 51:313-6
17. Bastidas RJ, Shertz CA, Lee SC, Heitman J, Cardenas ME. Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor. Eukaryot Cell 2012; 11:270-81
18. Chen SC-A, Lewis RE, Kontoyiannis DP. Direct effects of non-Antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species. Virulence 2011; 2:280-95
19. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-Active antifungal therapy: A case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-60
20. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: A study involving fly and murine models of zygomycosis. J Infect Dis 2009; 199:1399-1406
21. CLSI. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved Standard. 2nd ed. Document M38-A2. Wayne, PA: CLSI, 2008; 1-52
22. Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi MG, Walsh TJ. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 2002; 40:3204-8
23. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 2002; 40:3776-81
24. Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006; 50:96-103
25. Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-81
26. Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70:440-6
27. Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46:3001-12
28. Lehmann PF, White LO. Chitin assay used to demonstrate renal localization and cortisone-enhanced growth of Aspergillus fumigatus mycelium in mice. Infect Immun 1975; 12:987-92
29. Chamilos G, Lionakis MS, Lewis RE, et al. Drosophila melanogaster as a facilemodel for large-scale studies of virulencemechanisms and antifungal drug efficacy in Candida species. J Infect Dis 2006; 193:1014-22
30. Ben-Ami R, Lewis RE, Leventakos K, Latgé J-P, Kontoyiannis DP. Cutaneous model of invasive aspergillosis. Antimicrob Agents Chemother 2010; 54:1848-54
31. Howard SJ, Lestner JM, Sharp A, et al. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: Clinical implications for antifungal therapy. J Infect Dis 2011; 203:1324-32
32. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: Established and emerging indications. Antimicrob Agents Chemother 2008; 53:24-34
33. Heitman J. Cell biology: A fungal Achilles' heel. Science 2005; 309:2175-6
34. Cowen LE, Singh SD, Kohler JR, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A 2009; 106:2818-23
35. Cowen LE, Steinbach WJ. Stress, drugs, and evolution: The role of cellular signaling in fungal drug resistance. Eukaryot Cell 2008; 7:747-64
36. LaFayette SL, Collins C, Zaas AK, et al. PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog 2010; 6: E1001069
37. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53:958-66
38. Jang SH, Colangelo PM, Gobburu JVS. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: Evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88:115-9
39. High KP, Washburn RG. Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin). J Infect Dis 1997; 175:222-5
40. Moffatt SD, McAlister V, Calne RY, Metcalfe SM. Comparative efficacy of liposomal FK 506 with FK 506 (tacrolimus) with and without anti-CD4/CD8 monoclonal antibodies. Transplant Proc 1999; 31:2754
41. Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: Impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756-64
42. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE, Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008; 52:1556-8
43. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51:2587-90